Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation

Transplantation

Volumn 78, Issue 1, 2004, Pages 136-141

  Hardinger, Karen L ^a   Schnitzler, Mark A ^a   Miller, Brent ^a   Lowell, Jeffrey A ^a   Shenoy, Surendra ^a   Koch, Matthew J ^a   Enkvetchakul, Decha ^a   Ceriotti, Connie ^a   Brennan, Daniel C ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DATA BASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTRONICS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ADULT; ANTILYMPHOCYTE SERUM; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 3142726205     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000132329.67611.3F     Document Type: Article

References (10)

1. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded, comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011.
2. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843.
3. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118.
4. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with Thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473.
5. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29.
6. Muller TF, Grebe SO, Neumann MC, et al. Persistent long term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997; 64: 1432.
7. Preville X, Flacher M, Revillard JP, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a non-human primate model. Transplantation 2001; 71: 460.
8. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657.
9. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
10. Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplantation. Transplantation 1998; 65: 1270.